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ABSTRACT
The increasing numbers of genetic tests in clinical settings have identified many variants
of uncertain significance (VUS) in genes associated with inherited cardiac arrhythmias and
inherited cardiomyopathies. Evaluation of clinical practices including counseling strategies and
medical management recommendations for patients and their families is important to improve
patient outcomes and prevent over- or under-treatment that may result in morbidity or fatality.
The purpose of this study is to describe provider practices related to VUS results including how
they conduct risk assessments and ascertain what information and medical management
recommendations they provide to patients with VUS results and the patients’ family members.
Additionally, we aim to describe providers’ concerns and informational needs related to
counseling about a VUS. An anonymous online survey was developed for the current study and
distributed to genetic counselors through the National Society of Genetic Counselors (NSGC)
listerv and to cardiologists via emails obtained from publicly available resources. The survey
explored healthcare providers’ confidence in counseling about a VUS, explanation of a VUS to
patients, topics covered before and after genetic testing, and recommendations for patients with
a VUS and their families using clinical vignettes.
Providers (N=102) who completed the survey included 29 cardiovascular genetic
counselors, 50 genetic counselors from other specialties, and 23 cardiologists. A hypothetical
clinical scenario was used in which a young adult patient had a VUS in a gene causing
Arrhythmogenic Right Ventricular Cardiomyopathy, but did not meet clinical diagnostic criteria
for the condition. The patient’s only concerning issues included a personal history of fainting
during exercising and sudden death of a 45 year old first-degree relative. Nearly 9% of all
providers incorrectly described the VUS as likely pathogenic, while 15% would downplay the
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finding by indicating the VUS is more likely to eventually be reclassified as benign. Genetic
counselors feel more confident about counseling about VUS results (p<0.001). Both
cardiovascular genetic counselors and cardiologists feel confident in making medical
management recommendations; however, cardiologists are more likely to recommend treatment
with beta-blockers and exercise limitation for the patient. Compared to cardiac genetic
counselors, other genetic counselors (p=0.001) and cardiologists (p=0.014) were more likely to
recommend clinical testing for family members even though testing is expected to be
uninformative, especially given the absence of any clinical diagnosis in the family. These
findings highlight the expertise of different providers in different specialty area and suggest the
need for interdisciplinary clinics that include cardiologists, cardiac genetic counselors, nurses,
geneticists, psychologists and others to optimize care for challenging cases where VUS results
create uncertainty.
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INTRODUCTION
Inherited arrhythmias and cardiomyopathies are a group of genetic conditions that alter
the natural rhythm of the heart, causing fainting spells or sudden death (Priori et al., 2013). The
rapidly increasing numbers of genetic tests in clinical settings have identified many variants of
uncertain significance (VUS) in inherited cardiac arrhythmia and cardiomyopathy genes giving
rise to uncertainty among both patients and providers about appropriate clinical management.
Although the American College of Medical Genetics and Genomics (ACMG) have developed
standardized guidelines for variant classification, recent studies show that this process remains
a challenge, especially in the field of cardiology (Furqan et al., 2017; Reuter, Grove, Orland,
Spoonamore, & Caleshu, 2018; Richards et al., 2015). Interpretation of variants is a complicated
process that involves gathering information about the variant in addition to the laboratory
reports, including surveying variant databases, performing literature searches and consulting
with experts in the field (Reuter et al., 2018).
Uncertainty about a VUS result in inherited arrhythmia and cardiomyopathy genes not
only arises from the difficulty of classifying variants, but also from the reduced confidence that
the family history is reliable in accurately assessing risks due to incomplete gene penetrance.
Risk assessment is particularly important for inherited arrhythmias and cardiomyopathies since
the outcomes of failing to treat someone as high risk could result in fatality. Overdiagnosis and
overtreatment are additional concerns associated with inherited arrhythmias with possible
complications of infections, pneumothoraces and cardiac tamponade caused by surgical
management, and the burden of life long therapy with medications and unnecessary restriction
from excercise (Gaba et al., 2016; Hofman, Tan, Alders, van Langen, & Wilde, 2010; Schwartz
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et al., 2010). Due to these challenges associated with counseling about VUS results in inherited
arrhythmia and inherited cardiomyopathy genes, studies evaluating counseling practices are
needed, particularly given that most genetic counselors report the need for more cardiogenetic
education due to the recent emergence of this subspecialty (Somers et al., 2014).
Medical management, perceptions and genetic counseling practices related to VUS
results have been studied in cancer (C. L. Scherr, Lindor, Malo, Couch, & Vadaparampil, 2015;
Courtney L. Scherr, Lindor, Malo, Couch, & Vadaparampil, 2015). These studies show
increased anxiety in patients, incorrect recall of the results, physician’s lack of knowledge,
unnecessary surgeries and the need for more counseling resources (C. L. Scherr et al., 2015;
Welsh et al., 2017). Studies evaluating patients’ perception of an uninformative genetic test
result in cardiology showed incorrect recall of results, increased anxiety, reduced uptake of
family screening and lower rates of sharing the information with family (Burns, Yeates, Spinks,
Semsarian, & Ingles, 2017; Hamang et al., 2012; Hanninen et al., 2015).
The inherent challenges and uncertainties associated with VUS results in inherited
arrhythmia and inherited cardiomyopathy genes raises the question of how health care
providers discuss these results and implications this may have for patients and their family
members. We aim to describe counseling practices and needs across different health
professions including pre-test counseling, medical management recommendations,
management of uncertainty, evaluation strategies, the risk assessment process and information
shared with patients and their families. This study seeks to identify the needs and counseling
practices of health care providers as a first step toward revising counseling strategies that can
prevent unnecessary treatment, adverse outcomes caused by under-treatment and
inappropriate surveillance of at risk family members, and help manage uncertainty and improve
family sharing and surveillance.
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METHODS
The study was approved by the University of South Florida Institutional Review Board
(IRB). This is a descriptive study exploring healthcare providers’ self-reported practices related
to Variant of Uncertain Significance (VUS) results in genes associated with inherited
arrhythmias and cardiomyopathies.
Recruitment and Data Collection
A call to participate in the study was distributed once via email to genetic counselors
using the NSGC listserv and highlighted on the discussion board in the NSGC Cardiovascular
Special Interest Group (SIG). Contact was also attempted with 2000 cardiologists using email
addresses obtained from public resources and published articles. The recruitment email
included a brief description of the study and a link to both the informed consent form as well as
the Qualtrics survey.
Participants were eligible if they were able to understand and speak English, capable of
consenting, 18 years of age or older and genetic counselors, nurses, or physicians who have
seen at least one case referred for risk assessment for inherited cardiac arrhythmia or inherited
cardiomyopathy (e.g., Long QT syndrome, Short QT syndrome, Brugada syndrome, Familial
Hypertrophic Cardiomyopathy, Familial Dilated Cardiomyopathy, Arrhythmogenic Right
Ventricular Cardiomyopathy (ARVC), Familial Atrial Fibrillation (FAF), Catecholaminergic
polymorphic Ventricular Tachycardia (CPVT) and Cardiac Conduction Disease (CCD)).
Survey Instrument
The survey questions were specifically developed for the current study by the principal
investigator with the input of a cardiovascular genetic counselor, a medical geneticist and a
cardiologist with expertise in genetics. The final survey consisted of open- and close-ended
3

questions comprising of 3 sections to assess practice characteristics, clinical practices before
and after genetic testing (including healthcare providers’ confidence in counseling about a
VUS, explanation of a VUS to patients, topics covered before and after genetic testing, and
medical management recommendations for patients with a VUS and their families using a
clinical vignette), and informational sources and preferences of providers. Data was collected
over a 10 week period between 11/20/2018 and 01/31/2019.
Practice Characteristics
Participants were asked about 1) their profession and specialty areas 2) the number and
proportion of patients they have seen that were referred for inherited arrhythmias and/or
cardiomyopathies, 3) the number of VUS results in genes associated with inherited arrhythmias
and cardiomyopathies they have discussed with patients 4) primary work setting, 5) and the
number of providers in their practice providing risk assessment for these conditions.
Pre- and Post-test Counseling
Participants were asked to rate their general confidence in various aspects of both preand post-test counseling on a 5-point scale ranging from not at all confident (1) to extremely
confident (5).
Participants were asked how often they discuss various concepts during pre-test
counseling using a 5-point scale ranging from never (1) to always (5). A clinical scenario was
developed by the authors to inquire about participants’ practices when their patient receives a
VUS result. The clinical vignette described a young adult patient with a VUS in a gene causing
Arrhythmogenic Right Ventricular Cardiomyopathy, a genetic condition that can present with
both cardiomyopathy and abnormal heart rhythm. The vignette stated that the patient had a
history of fainting, but did not meet clinical diagnostic criteria for the condition and the patient’s
only concerning family history included sudden death of a 45-year-old first-degree relative.
Subsequent questions asked participants to indicate on a 5-point scale how likely or unlikely it is
that they would 1) provide certain information to the patient, 2) give various medical
4

management recommendations, 3) encourage patients with a VUS to share certain information
with their family members and 4) utilize specific counseling strategies with the patient described
in the clinical scenario. Participants were also asked to rate their confidence in making medical
management decisions on a 5-point scale ranging from not at all confident (1) to extremely
confident (5).
Informational Sources and Preferences
Participants were asked 1) how often they use certain informational sources when they
receive a VUS result, and 2) what information they would find helpful in a VUS database.
Data Analysis
Participants were grouped into three groups based on their profession and specialty
including cardiovascular genetic counselors, other genetic counselors and cardiologists.
Frequencies and medians for questions that measured practice characteristics, clinical practices
and informational sources were obtained using SPSS.
An average score from 5 questions assessing confidence in counseling was created and
medians of the average scores for each group were reported. Results for questions related to
topics discussed before ordering a genetic test and to additional informational sources used to
evaluate a VUS result were reported by combining the proportion of respondents who would
often (score 4) or always (score 5) would discuss the listed topics. Results for questions related
to topics discussed during result disclosure were reported by medians. Results for the question
related to confidence in making medical management recommendations were reported by
combining the proportion of respondents who feel very (score 4) or extremely confident (score
5). Results for questions related to medical management recommendation, information to share
with family members and counseling strategies used were reported by combining the proportion
of respondents who would likely (score of 4) or extremely likely (score of 5) follow the described
clinical practices. Various medical management recommendation questions were then grouped
into seven groups representing those who were very likely or extremely likely to: 1) treatment
5

with Beta-blockers, 2) treat the patient with a VUS with surgical interventions including ICD,
cardiac catheter ablation and/or pacemaker, 3) limit exercising 4) conduct further clinical
evaluation for the patient including cardiac MRI, exercise stress test, and/or evaluation by Holter
monitor, and 5) recommend yearly cardiology follow-up with ECGs, echocardiograms, or
cardiology visits; 6) no medical management changes and 7) yearly follow-up with genetics.
Comparisons of confidence and medical management recommendations for both the
patients and their family members across groups and post-hoc analyses when a statistically
significant differences were found were done by using nonparametric tests and adjusting for
multiple comparisons. Comparisons across three groups were made by using Kruskal-Wallis
tests and adjusting for multiple comparisons using a Bonferroni correction for each group of
questions related to medical management of the patient and recommendations for at risk family
members. Post-hoc analysis was done by using Mann-Whitney U tests.
Qualitative analysis of open-ended questions was done by using an inductive approach.
Responses were reviewed and coded into themes including uncertainty about the clinical
diagnosis, need for further clinical evaluation, need to manage patients based on personal and
family history, need for post-mortem testing of deceased relative, cardiac evaluation of at-risk
relatives, genetic testing for at risk relatives and not ordering genetic testing for this patient in
the first place.
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RESULTS
Participants
A total of 120 survey responses were received. Thirty of the respondents were
cardiovascular genetic counselors (GCs), 55 of were genetic counselors working in other
specialties and 23 were cardiologists. Surveys were excluded from data analysis if the
respondent completed less than 50% of questions. A total number of 102 surveys were included
in the data analysis; 29 cardiovascular GCs, 50 GCs working in other specialties and 23
cardiologists (Figure 1).

Figure 1. Sampling and Respondents.
Note: 12 participants started the survey; however, they did not fill out their profession. These
surveys were excluded. a5 Cardiovascular genetic counselors and b 3 other genetic counselors
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didn’t finish the survey but completed more than 50% of questions. These surveys were
included in the data analysis.

Practice Characteristics
A vast majority of cardiovascular GCs (93.1%) and cardiologists (78.3%) have seen
more than 20 patients to assess risk of inherited arrhythmias or cardiomyopathies, while only
34% of other GCs have seen more than 20 patients (Table 1.) A majority of cardiovascular GCs
and cardiologists work in a University Medical Center compared to only 38% of other GCs.
Participants work with varying numbers of other healthcare providers ranging from one to over
five in the same clinical practice.
Pre-test Counseling
All GCs and the majority of cardiologists (77.3%) discuss the possibility of getting a VUS
result before genetic testing is ordered. All cardiovascular GCs, 96% of other GCs and 81% of
cardiologists discuss the risks and benefits associated with genetic testing. Most providers also
talk about the implication of genetic testing for family members including sharing the results with
them (83.3%, 89.6% and 77.3% of other GCs, cardiovascular GCs and cardiologists
respectively) and the importance of clinical evaluation of at-risk family members (100%, 91.7%
and 85.7% of cardiovascular GCs, other GCs and cardiologists respectively). Less commonly
discussed topics before genetic testing include the uncertainty about medical management if the
test results are uninformative with only 68.8% of other GCs, 58.6% of cardiovascular GCs and
50% of cardiologists discussing this topic often or always. Discussion about laws protecting
against healthcare insurance and employment discrimination based on genetic test results and
their limitations before ordering a genetic test is often or always done by 68.9% of
cardiovascular GCs, 66.7% or other GCs and 57.1% of cardiologists (Figure 2.).
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Table 1. Practice Characteristics
Practice Characteristics

Cardiovascular
Genetic Counselors
(n=29)

Other Genetic
Counselors a
(n=50)

Cardiologist
s b (n=23)

Number of patients seen for
inherited arrhythmias and
cardiomyopathies
1-5
17 (34%)
2 (8.7%)
6-10
9 (18%)
2 (8.7%)
11-20
2 (6.9%)
7 (14%)
1 (4.3%)
>20
27 (93.1%)
17 (34%)
18 (78.3%)
Primary work setting
University Medical Center
20 (69%)
19 (38%)
22 (93.7%)
Private Medical Facility
14 (28%)
1 (4.3%)
Public Medical Facility
8 (27.6%)
11 (22%)
Health Maintenance
1 (2%)
Organization
Other
1 (3.4%)
5 (10%)
Total number of healthcare
providers in practice
1
5 (17.2%)
10 (20%)
2 (8.7%)
2
4 (13.8%)
11 (22%)
4 (17.4%)
3
6 (20.7%)
10 (20%)
4
3 (10.3%)
5 (10%)
5 (21.7%)
>5
11 (37.9%)
14 (28%)
12 (52.2%)
Percentage of patients seen
for inherited arrhythmias and
cardiomyopathies
<10%
2 (6.9%)
37 (74%)
17 (73.9%)
10-24%
8 (16%)
25-50%
4 (13.8%)
3 (6%)
3 (13.1%)
51-75%
3 (10.3%)
1 (2%)
2 (8.7%)
>75%
20 (69%)
1 (2%)
1 (4.3%)
Number of patients seen with
a VUS result in inherited
arrhythmia and
cardiomyopathy genes in the
past year
0
19 (38%)
3 (13%)
1-10
3 (10.3%)
22 (44%)
12 (52.2%)
11-20
5 (17.2%)
6 (12%)
4 (17.4%)
21-30
7 (24.1%)
>30
14 (48.3%)
3 (6%)
2 (8.7%)
Genetic Counseling Board
certification
Board Certified
26 (90%)
45 (90%)
Board Eligible
3 (10%)
5 (10%)
Note: a specialty areas of these counselors include: cancer (24%), prenatal (16%), pediatrics
(30%), adult (18%), and other: neurology, nephrology, metabolic, newborn screening, research,
9

ophthalmology and endocrinology (12%). b Specialty areas of these cardiologists include:
electrophysiologist (26%), adult cardiologist (65%), and heart failure cardiologist (9%).

Percent of respondents

Cardiovascular Genetic Counselors
100
90
80
70
60
50
40
30
20
10
0
Possibility
of a variant
of uncertain
significance
(VUS) result

Uncertainty about
medical
management
recommendations
based on an
uninformative test
result

Other Genetic Counselors

Sharing test
result
information
with family
members

The
importance
of at risk
family
members
being

Cardiologists

Risks and Insurance
implication
benefits
associated
with testing

Figure 2. Percent who would often or always discuss various topics prior to genetic testing.

Post-test Counseling
When asked which response best captures what providers would say about the VUS
result to the patient in the scenario, most selected the option ‘At this point, we don’t have
enough information on this variant to determine for certain if the gene change is causing your
family history of sudden death and your symptoms.’ A total of 8.8% of all providers (6.1%, 7.1%
and 28.6% of GCs, cardiovascular GCs and cardiologists respectively) would describe these
results as likely pathogenic as evidenced by selecting the following response ‘At this point, we
just don’t have enough information on this variant to determine if it causing your symptoms and
your family history, but I think it probably is’. Finally, 14.7% of all providers would be more
10

reassuring about these results and downplay the finding by explaining that ‘Most VUS results
end up being found to be normal variation that is not associated with disease risk, but we just
don’t have enough information to determine if this variant is or is not responsible for your family
and personal history.’ (Figure 3.) Five respondents explained in comments that they would
prefer to do more clinical evaluation before they would explain the results to the patient. These
responses were excluded from the analysis and valid percentages are reported.

100

Percent of respondents

90
80

70
60
50
40
30

20
10
0
At this point, we just don’t have
At this point, we don’t have enough Most VUS results end up being found
enough information on this variant to
information on this variant to
to be normal variation that is not
determine if it causing your
determine for certain if the gene
associated with disease risk, but we
symptoms and your family history, change is causing your family history just don’t have enough information to
but I think it probably is.
of sudden death and your symptoms. determine if this variant is or is not
responsible for your family and
personal history.

Cardiovascular Genetic Counselors

Other Genetic Counselors

Cardiologists

Figure 3. How VUS results were explained to the patient.

The likelihood of discussing various topics during result disclosure varied widely across
groups. All three groups were very or extremely likely to discuss what it would mean for the
patient if the VUS was reclassified. Genetic counselors are not likely to discuss risks associated
with treatment or lack of treatment or the information considered in variant classification, while
cardiologists are more likely to discuss these topics. All providers are moderately to very likely
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to provide written information to the patient about VUS results and the cardiovascular condition
(Figure 4). Additional written comments from cardiovascular and other GCs emphasized the
importance of highlighting that based on the personal, family and genetic testing history, this
patient does not meet clinical diagnostic criteria for an inherited cardiovascular conditions;
however, she is at an increased risk based on her family and personal history alone as
illustrated in the following quote: “…her personal and family history may predispose her to
sudden cardiac death even though she does not meet criteria for a known clinical condition
associated with sudden cardiac death”. A couple of respondents indicated that for the individual
described in their hypothetical clinical scenario, they would not have ordered panel genetic
testing to an unaffected individual.

Cardiovascular Genetic Counselors
5

Median score

4

Other Genetic Counselors Cardiologists
1=Not at all likely
2=Somewhat likely
3=Moderately likely
4=Very likely
5=Extremely likely

3
2
1
0
What it would mean
if the VUS was
reclassified

Risks of treatment
Information
and no treatment conisdered in variant
classification

Provide written
information

Figure 4. Median likelihood of discussing various topics when disclosing VUS results. a
Note: aEach individual's Likert-type responses to several questions within each topical category
were averaged and then medians for the three groups were calculated.
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Confidence
There was a statistically significant difference across the three groups in level of
confidence in counseling about a VUS result (p<0.001) with both cardiovascular and other
genetic counselors reporting a higher level of confidence than cardiologists (p=0.001) in
counseling about VUS results (Figure 5.)

Cardiovascular Genetic Counselor

4

Other Genetic Counselors
Cardiologists
1=Not at all confident
2=Somewhat confident
3=Moderately confident
4=Very confident
5=Extremely confident

3

*

Median score

5

2
1
0

Figure 5. Median levels of confidence in counseling about a VUS result. a
Note: a Each individual’s scores on 5 Likert-type questions were averaged and then medians for
the three groups were calculated.* A statistically significant difference was found between the
three groups (p<0.001). Post-hoc analyses showed cardiologists differed significantly from
cardiac genetic counselors (p<0.001) and other genetic counselors (p=0.001)

Confidence in making medical management recommendations was also statistically
significantly different across the three groups (p=0.002). Other GCs compared to cardiovascular
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genetic counselors (p=0.001) and cardiologists (p=0.01) reported less confidence in making
medical management recommendations if they were asked to (Figure 6.)

Cardiovascular Genetic Counselors

Other Genetic Counselors

Cardiologists

100

Percent of respondents

90
80
70
60
50
40
30

20

*

10
0

Figure 6. Proportions who are very or extremely confident in making medical management
recommendations for the patient with a VUS.
Note: *Kruskall-Wallis test showed a statistically significant difference between groups
(p=0.002). Post-hoc analyses by Mann-Whitney U tests found other genetic counselors differed
significantly from cardiac genetic counselors (p=0.001) and cardiologists (p=0.01).

Medical Management Recommendations
Forty-four percent of cardiologists, 6.7% of cardiovascular GCs and 33.3% of other GCs
would be very or extremely likely to recommend some treatment with Beta-blockers. None of the
genetic counselors and only a small percentage of cardiologists (11.1%) would recommend
treatment with surgical intervention including ICD, cardiac catheter ablation and/or pacemaker.
While none of the cardiovascular GCs would recommend limiting exercise as treatment, almost
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half of cardiologists (43.8%) and 28.6% of other GCs would. The three groups have a
statistically significant difference (p=0.001) with cardiovascular GCs less likely to recommend
exercise limitations than other GCs (p=0.006) and cardiologists (p=0.001). Most providers in all
three groups (91.3% of cardiovascular GCs, 94.7% of cardiologists and 71.4% of other GCs)
would likely to recommend further cardiac evaluation in the form of cardiac MRI, exercise stress
test, and/or evaluation by Holter monitor. Cardiovascular GCs (73.9%), other GCs (71.4%) and
cardiologists (78.9%) were also likely to recommend yearly follow-up visits with a cardiologist
including yearly ECGs, echocardiograms, and/or cardiology visits to evaluate the disease state.
A majority of respondents selected that there should be some medical management changes
made with only 25% of cardiovascular GCs, 8.7% of other GCs and 16.7% of cardiologists
believing that no medical management changes should be made. Although 50% of
cardiovascular GCs and 57.8% of other GCs would recommend yearly follow up with genetics,
only 16.7% of cardiologists reported that they would likely recommend genetics follow-up as
part of medical management.
Open-ended comments from respondents supported these findings, highlighting the
perceived importance of further evaluation and cardiac and genetics follow-up. Multiple
respondents indicated that post-mortem genetic testing and/or autopsy report on the deceased
relative would be part of their clinical investigation: ‘Additionally, would clarify if sample available
for post-mortem genetic testing of family member as well as additional records regarding
autopsy of this individual.’ Comments emphasized the importance of treating a patient with a
VUS based on personal and family history without considering the VUS result when making a
plan for medical management: ‘Would recommend routine echo/ECG based on her family
history of SCD in 1st degree relative alone. VUS not necessarily prompting those evaluations.’
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Cardiovascular Genetic Counselors

Other Genetic Counselors

Cardiologists

Percentage of respondents

100
90
80
70
60
50

*

40
30
20
10
0

Beta Blockers

Surgical
treatment

Yearly
Limiting Further
Yearly
No medical follow
excercise evaluation cardiology management
up with
follow-up changes
genetics

Figure 7. Proportions who would likely or very likely make the following medical
recommendations for the patient with a VUS.
Note: *Kruskall-Wallis test showed a statistically significant difference among groups (p=0.001).
Post-hoc analyses by Mann-Whitney U tests found that cardiovascular genetic counselors
differed significantly from other genetic counselors and cardiologists (p=0.006 and p=0.001
respectively). Proportions who would likely or very likely do one or more of the following

a

surgical treatment options (ICD, cardiac catheter ablation and/or pacemaker); b further
evaluations (cardiac MRI, exercise stress test, and/or evaluation by Holter monitor); c yearly
follow-up (ECGs, echocardiograms, and/or cardiology visits).

Family Sharing
There is variability across providers about what topics they would recommend patients
share with their family members. Most respondents would recommend sharing the genetic test
report with family members (41.7%, 61.2%, 55.6% of cardiovascular GCs, other GCs and
cardiologists respectively), discussing the risk of having an inherited genetic condition (50%,
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57.1%, 77.8% of cardiovascular GCs, other GCs and cardiologists respectively) and discussing
the option of genetic counseling (45.8%, 58.3% and 64.7% of cardiovascular GCs, other GCs
and cardiologists respectively). Cardiac evaluation of at-risk family members was recommended
by most cardiovascular GCs (95.7%) and cardiologists (83.3%); however, most of the other GCs
did not find it important with only 32.7% of them recommending clinical evaluation of at risk
family members. Cardiologists (58.8%) and other GCs (58.3%) are significantly more likely to
recommend genetic testing for at risk family members (p=0.014 and p=0.001 respectively)

Percent of respondents

compared to cardiovascular GCs (6.9%).

Cardiovascular Genetic Counselors Other Genetic Counselors Cardiologists
100
90
80
70
60
50
40
30
20
10
0
Recommendation Recommend
Recommendation
Patient's
Possibility of
for clinical genetic -ation of
having a genetic genetic test that certain family
testing of other
cardiac
members
report
cardiovascular
family members to evaluation
consider
genetic
condition based
see who else has for other
counseling
on family history
the variant
family
members

*

Figure 8. Proportions who would likely or very likely recommend the patient with a VUS share
the following with family members.
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Counseling Strategies
The most frequently used counseling strategies for a patient with an uncertain or
inconclusive result in all three groups were checking for patient understanding (100%, 100%,
83.3% of cardiovascular GCs, other GCs and cardiologists respectively) and exploring patient
concerns (100%, 95.9%, 83.3% of cardiovascular GCs, other GCs and cardiologists
respectively). Most providers would discuss different sources of uncertainty (87.5% of
cardiovascular GCs, 87.7% of other GCs and 72.2% of cardiologists) and the uncertainty related
to the variability and severity of inherited cardiac conditions (88% of cardiovascular GCs, 77.1%
of other GCs and 83.3% of cardiologists). Less frequently used counseling approaches across
all three providers are helping patients identify ways that they can feel in control of their lives
(44%, 55.1%, 55.6% of cardiovascular GCs, other GCs and cardiologists respectively) and
helping patients create a plan to deal with uncertainty (44%, 62.5%, 61.1% of cardiovascular
GCs, other GCs and cardiologists respectively). Finally, 20.9% of cardiovascular GCs, 36.8% of
other GCs and 44.4% of cardiologists would refer their patient for additional, long term
counseling if they felt it was indicated (Figure 9.)
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Figure 9. Proportions who would be very or extremely likely to use the following counseling
strategies.
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Informational Needs
The least frequently utilized resource to gather more information about a VUS in all three
groups was contacting researchers (4.2% of cardiovascular GCs, 18.4% of other GCs and
41.2% of cardiologists). Most providers would use the supplemental information included in the
laboratory report (79.2%, 87.2%, 58.9% of cardiovascular GCs, other GCs and cardiologists
respectively), search the scientific literature (83.4%, 81.3%, 70.6% of cardiovascular GCs, other
GCs and cardiologists respectively), review databases (95.8%, 85.7%, 47.1% of cardiovascular
GCs, other GCs and cardiologists respectively), and discuss the results with colleagues (83.4%,
77.5%, 70.6% of cardiovascular GCs, other GCs and cardiologists respectively) to gain more
insight into the clinical meaning of a VUS. Cardiologists less frequently contact the laboratory
about their variant classification program (25.1%) than cardiovascular (50%) or other GCs
(69.4%) (Figure 10).
Cardiovascular Genetic Counselors

Other Genetic Counselors

Cardiologists

100

Percent of respondents

90
80
70
60
50
40
30

20
10
0

Supplemental
information
included with
test results
from the
laboratory

Contact
laboratory
about variant
classification
program

Contact
researcher
working in this
area of
genetics

Search the
scientific
literature
for
publication

Search
variant
databases

Discuss
with
colleague

Figure 10. Proportion who would often or always use the following resources to learn more
about a VUS.
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Most genetic counselors would find it helpful if the following information was available in
variant databases: allele frequencies, computer modeling of functional effect on protein function,
references to scientific publications, results of segregation studies, location of the variant, type
of mutation, whether the variant has been reported before and whether the variant was found in
patients with symptoms. Cardiologists were less likely to find the above-mentioned information
helpful (Figure 11).
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Figure 11. Proportions who would find the following database information helpful.
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DISCUSSION
Genetic testing is becoming more common and are ordered by a variety of healthcare
providers. This study aimed to evaluate the clinical practices of both providers who have
specialized genetic training and those who don’t in a cardiovascular setting in order to obtain a
broad description of the clinical practices related to VUS results. To our knowledge, this is the
first study assessing clinical practices related to VUS results in genes associated with inherited
arrhythmias and cardiomyopathies. Based on our findings, the possibility of getting a VUS result
is frequently discussed prior to testing; however, the possibility that an uninformative test result
may increase rather than reduce uncertainty associated with inherited cardiovascular conditions
is discussed less frequently. The negative impact of VUS results on patients’ risk perceptions,
distress related to the condition, sustained levels of anxiety and depression have been
established in the cancer setting (Culver et al., 2013; O’Neill et al., 2009; Vos et al., 2008;
Welsh et al., 2017). In the cardiovascular setting, studies show dissatisfaction, reduced familial
screening and incorrect recall of results in VUS result recipients (Burns et al., 2017; Lawal et al.,
2018). Additionally, uncertainty and ambiguity can result in distress manifesting in both
behavioral (for example avoidance) and cognitive symptoms (for example cardiac event related
fear) among cardiovascular patients (Rhodes et al., 2017). Ingles and Semsarian (2014a)
describe the importance of discussing the inherent uncertainty associated with genetic testing
for inherited cardiovascular conditions during pre-test counseling (Ingles & Semsarian, 2014a).
The authors describe the need to convey the probabilistic nature of genetic testing, the chances
of receiving an uninformative test result, implications of a VUS result to family members and the
possibility of reclassification (Ingles & Semsarian, 2014a). More frequent and detailed
discussion of implications of VUS results before genetic testing may help patients make a more
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informed decision. Furthermore, it is important to address the level of perceived uncertainty
because perceptions of uncertainty after genetic testing can affect individuals’ decisions to
learn, interpret, and act on recommendations (Biesecker et al., 2014). This study found that in
the described clinical scenario, without additional information available, most providers would
describe a VUS result as truly uncertain during result disclosure; however, a small subset of
providers incorrectly described the VUS as likely pathogenic raising concerns about introducing
unnecessary worry, anxiety and distress to patients and subsequently increasing negative
psychological outcomes.
Almost half of cardiologists in this study would recommend some type of treatment
including therapy with medication, exercise limitation and less frequently ICDs to the individual
described in the hypothetical scenario who received a VUS result and lacked a clinical diagnosis
of an inherited cardiovascular condition. Decisions about treatment in a genetically and clinically
uncertain scenario described are complicated by the risks of over- and under-treatment and the
risk of possibly fatal outcome of first presenting symptom. Additionally, over-treatment and overdiagnosis has reportedly been an issue for inherited arrhythmias and cardiomyopathies
potentially resulting in adverse physical and psychological patient outcomes (Furqan et al.,
2017; Gaba et al., 2016; Schwartz et al., 2010). While ACMG guidelines do not recommend
medical management changes solely based on a VUS result, these guidelines are not specific
to inherited cardiovascular conditions and cardiologists may have more experience with
weighing the risks and benefits of treatment in an uncertain case (Green et al., 2013). Our study
also supported this assumption by showing that cardiologists were more likely to discuss the
risks and benefits associated with treatment and the lack of it and feel more confident in making
medical management recommendations compared to other genetic counselors. On the other
hand, both cardiovascular genetic counselors and other GCs reported a higher level of
confidence in counseling about VUS results in general compared to cardiologists and were likely
to recommend regular follow-up with genetics. Regular follow-up with genetics is important in
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providing information to patients about variant reclassification and updating medical and family
history. As additional information is gathered over time, the uncertainty associated with these
cases can be resolved. Several articles have argued that genetic counselors may be in the
perfect position to help cardiologists understand the implications of complex genetic information
to care for patients and their family members (Ackerman et al., 2011; Caleshu, Day, Rehm, &
Baxter, 2010; Dunn, Caleshu, Cirino, Ho, & Ashley, 2013; Ingles, Yeates, & Semsarian, 2011).
Additionally, genetic counselors are trained in delivering complex information in a sensitive
manner which may improve negative psychological outcomes (Ingles et al., 2011). These
findings highlight the unique expertise of different providers and the importance of
communication between different specialties.
Another key finding that has important implications is that over half of cardiologists and
genetic counselors would recommend clinical genetic testing for the familial VUS for family
members even though testing is expected to be uninformative in the described scenario, where
segregation study is not possible due to the lack of symptomatic relatives. This finding is
concerning because testing family members for a VUS in this case would have no clinical utility
and could lead to harm if unaffected individuals are treated based on the presence of a VUS
and those without the VUS are released from cardiac surveillance (Arscott et al., 2016; Ingles &
Semsarian, 2014b). Furthermore, predictive genetic testing for a VUS results in wasting
healthcare dollars and may introduce unreasonable reassurance or unnecessary worry in family
members.
Practice Implications
Inclusion of genetic counselors in the care of patients who are at risk for inherited
cardiovascular conditions has been recommended in clinical practice guidelines and consensus
statements (Ackerman et al., 2011; Gersh et al., 2011; Hershberger et al., 2018). Genetic
counselors have unique training in pedigree analysis, identifying the most appropriate individual
to test and most appropriate test to order resulting in the reduction of unnecessary healthcare
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costs (Arscott et al., 2016). Multiple studies highlighted the benefits of an interdisciplinary care
team for inherited cardiovascular conditions with the involvement of genetic counselors,
cardiologists, geneticists, nurses, psychologists, and others (Erskine et al., 2013; Ingles et al.,
2011). Studies show that hypertrophic cardiomyopathy patients who attend specialized
cardiovascular genetics clinics have low distress, good adjustment, appropriate risk perception
and compliance with medical recommendations related to understanding the condition, time
spent with the patients and having a good clinical relationship with healthcare providers,
highlighting the value of an interdisciplinary care team (Ingles, Lind, Phongsavan, & Semsarian,
2008).
Study Limitations
Our study was limited by our ability to calculate response rate because we don’t have
information on how many genetic counselors received the survey through the listerv and how
many cardiologists opened the invitation email. The results are limited by the small sample size
and the self-selecting nature of the study population. We anticipate this may bias the results to
be more representative of providers who have more interest in the topic, who specialize in
cardiogenetics and have significantly more experience than other providers. Another limitation is
that the survey instrument was developed specifically for this study and it has not been
validated before. Given that the survey was already quite long we had to reduce the number of
questions and there are aspects of clinical practices related to VUS results that were not
explored. Future studies could explore these clinical practices by interviewing providers.
Finally, data were self-reported and may not reflect actual practice. We aimed to be as
detailed and specific as possible by giving a clinical scenario related to VUS results to help
provide a concrete point of reference. However, it is possible that clinical practices related to a
VUS result would change if certain aspects of the scenario were altered, such as the condition,
family history or personal symptoms. Future studies could evaluate how these different factors
might change clinical practices.
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Research Recommendations
Our study was limited by the small sample size and possible self-selection bias limiting
the generalizability of this study. Additionally, qualitative studies or review of actual patient visits
may provide a more detailed and accurate insight into genetic testing and counseling practices.
Finally, a better understanding of how patients perceive VUS results and what they need to be
able to manage the inherent uncertainty associated with them can help develop counseling
strategies for managing uncertainty and ultimately improve patient outcomes (Lawal et al.,
2018).
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Appendix A: Informed Consent to Participate in Research
Information to Consider Before Taking Part in this Research Study
Pro # 00036645
Researchers at the University of South Florida (USF) study many topics. To do this, we need
the help of people who agree to take part in a research study. This form tells you about this
research study. We are asking you to take part in a research study that is called: Clinical
practices related to variant of uncertain significance (VUS) results in cardiac arrhythmia and
inherited cardiomyopathy genes. The person who is in charge of this research study is Reka
Muller. This person is called the Principal Investigator.
Purpose of the Study
The purpose of this study is to explore informational needs and communication practices of
healthcare providers who conduct genetic testing for inherited arrhythmias and inherited
cardiomyopathies. Our focus is on current communication practices and informational sources
and needs about variant of uncertain significance (VUS) results.
Our long term goal is to help health care professionals provide the best possible care when
counseling about VUS results related to cardiac arrhythmias and inherited cardiomyopathies. By
evaluating providers’ needs and practices in communicating about VUSs, we can develop better
resources.
Why are you being asked to take part?
We are asking you to take part in this research study because you are a provider who sees
patients regarding inherited arrhythmias and/or inherited cardiomyopathies.
Study Procedures
If you take part in this study, you will be asked to fill out an online survey. The survey will ask
about your practice characteristics, counseling practices before a genetic test is ordered, your
informational sources and needs about a VUS result and your communication practices related
these results. Your responses will be anonymous and will not be linked to your identity. This is a
one-time survey that will take approximately 10-15 minutes to complete.
Alternatives / Voluntary Participation / Withdrawal
You have the alternative to choose not to participate in this research study.
You should only take part in this study if you want to volunteer; you are free to participate in this
research or withdraw at any time. There will be no penalty or loss of benefits you are entitled to
receive if you stop taking part in this study. Your decision to participate or not to participate will
not affect your job status, employment record, employee evaluations, or advancement
opportunities.
Benefits and Risks
We are unsure if you will receive any benefits by taking part in this research study.
This research is considered to be minimal risk.
Compensation
We will not pay you for the time you volunteer while being in this study.
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Privacy and Confidentiality
We will do our best to keep your records private and confidential. We are not collecting any
personally identifying information, but we cannot guarantee absolute confidentiality. It is
possible, although unlikely, that unauthorized individuals could gain access to your responses
because you are responding online.
Certain people may need to see your study records. The only people who will be allowed to see
these records are: Reka Muller (PI), Dr. Deborah Cragun (Faculty Advisor), others on Reka’s
thesis committee, The University of South Florida Institutional Review Board (IRB).
It is possible, although unlikely, that unauthorized individuals could gain access to your
responses. Confidentiality will be maintained to the degree permitted by the technology used.
No guarantees can be made regarding the interception of data sent via the Internet. However,
your participation in this online survey involves risks similar to a person’s everyday use of the
Internet. If you complete and submit an anonymous survey and later request your data be
withdrawn, this may not be possible as the researcher will be unable to extract anonymous data
from the database.
We may publish what we learn from this study. We will not publish anything that would let
people know who you are.
There will be no identifiable personal information collected in this study. The data collected for
this research will be kept as long as it is needed to conduct this research. Once your
participation in the research is over, your information will be stored in accordance with
applicable policies and regulations.
If you have concerns about the use or storage of your personal information, you have a right to
lodge a complaint with the data supervisory authority in your country.
Contact Information
If you have any questions about your rights as a research participant, please contact the USF
IRB at (813) 974-5638 or contact by email at RSCH-IRB@usf.edu. If you have questions
regarding the research, please contact the Principal Investigator at rekamuller@health.usf.edu.
You can print a copy of this consent form for your records.
I freely give my consent to take part in this study. I understand that by proceeding with this
survey that I am agreeing to take part in research and I am 18 years of age or older.
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Appendix C: Cardiogenetics and Variant of Uncertain Significance Questionnaire
The following questions ask for information about your clinical experiences related to Inherited
Arrhythmia and Cardiomyopathy risk assessment and testing.
1. Approximately how many patients have you talked to about risks for inherited
arrhythmias and/or inherited cardiomyopathies?
0
1-5
6-10
11-20
>20
(Thank you for your participation! We are interested in learning more about providers who have
experience talking to at least one patient about inherited arrhythmias.)
2. Which of the following best describes your primary work setting?
University Medical Center
Private Hospital/Medical Facility
Public Hospital/Medical Facility
Diagnostic Laboratory
Physician's Private Practice
Health Maintenance Organization
University/Non-Medical Center
Other (please specify):
3. Including yourself, how many individuals provide risk assessment for inherited
arrhythmias and/or inherited cardiomyopathies in your practice setting?
1
2
3
4
5 or more

4. What is your profession?
Cardiac Electrophysiologist
Adult cardiologist
Pediatric cardiologist
Medical/Clinical Geneticist
Primary Care Physician
Genetic Counselor
Nurse Practitioner
Other (please specify):
Automatic branching genetic counselor and geneticist, will be asked questions 5-7.

5. Are you board certified in genetic counseling or medical genetics?
Yes
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No, exam taken and awaiting results
No, but I am board eligible in genetics
No, I am not board eligible in genetics
6. Please select your primary specialty area (Please check only one option):
Cancer
Prenatal
Pediatric
Adult
Cardiovascular
Other (please specify):
7. Please select any additional practice area(s), if applicable (select ALL that apply):
None
Cancer
Prenatal
Pediatric
Adult
Cardiovascular
Other (please specify):
8. Approximately what percentage of patients seen in your clinic are referred for risk
assessment for inherited arrhythmias and/or inherited cardiomyopathies?
<10%
10-24%
25-50%
51-75%
>75%
9. In the last year, about how many patients have you seen with a variant of uncertain
significance (VUS) in inherited arrhythmia or cardiomyopathy genes? (Do not include
"pathogenic", "likely pathogenic, "likely benign" or "no mutation detected" results)
0
1-5
6-10
11-20
21-30
31-40
>40
10. At your institution, who would help patients at increased risk for inherited arrhythmias or
inherited cardiomyopathies make medical management decisions? (select all that apply)
Cardiologist
Medical/Clinical Geneticist
Primary Care Physician
Genetic Counselor
Nurse Practitioner
Other (please specify):
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11. At your institution, who typically discusses options about genetic testing for family
members for inherited arrhythmia or cardiomyopathy genes? (select all that apply)
Cardiologist
Medical/Clinical Geneticist
Primary Care Physician
Genetic Counselor
Nurse Practitioner
Other (please specify):
12. Please indicate on a scale of 1-5 (1= not at all confident, 5=extremely confident) how
confident you feel that you are able to do the following for a patient with a VUS in an
arrhythmia or cardiomyopathy gene? If this is not applicable to your clinical
responsibilities please select that option.
Not
applicable
to my
clinical
role

Not at all
confident
(1)

Somewhat
confident
(2)

Moderately
confident
(3)

Very
confident
(4)

Extremel
y
confident
(5)

Evaluate
supporting
evidence for the
classification of
the VUS
Explain what a
VUS result is to
a patient
Explain whether
a VUS result
would change
the patient’s
risks
Provide
psychosocial
support to
patients with a
VUS
When
appropriate,
assist patients
in
communicating
a VUS result to
family members
13. On a scale of 1-5 (1=Never, 5=Always) how often do you discuss the following with
patients about genetic testing before the testing is ordered for inherited arrhythmias
and/or inherited cardiomyopathies?
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Never
(1)

Rarely
(2)

Possibility of a variant of
uncertain significance (VUS)
result
Number of genes included on
a panel test
Different types of genes
included on a panel test
Possibility of not getting a
definitive yes or no answer
from genetic testing
How different test results may
or may not change treatment
options
Uncertainty in gene variant
classification across
laboratories
Uncertainty about medical
management
recommendations based on
an uninformative test result
Uncertainty about prognosis if
a pathogenic variant is
identified in a gene with
reduced penetrance
Sharing test result information
with family members
The importance of at risk
family members being
evaluated
Patient’s own reasons for
wanting or not wanting testing
Risks and benefits associated
with testing
Possibility of lifestyle changes
based on the test result
Anticipated or possible
reactions of the patient to a
VUS result
Issues about disability and
long-term care insurance
The extent to which laws
protect against discrimination
by health insurers and
employers
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Sometimes
(3)

Often
(4)

Always
(5)

I don’t
know

The following questions refer to the following scenario:
You are seeing a patient with a VUS result in PKP2, one of the genes associated with
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). ARVC is characterized by fibrofatty
replacement of the myocardium that can cause cardiomyopathy, arrhythmia, heart failure and
sudden death. She is 25 years old with a personal history of fainting during exercise on a few
occasions and a normal ECG. Her echocardiogram appeared normal. She does not meet
clinical diagnostic criteria for ARVC. She has a family history of sudden cardiac death at age 45
in one first degree relative and no other concerning family history.
14. Assuming you have no information that would lead you to believe this VUS is more likely
benign or more likely pathogenic, which statement most closely matches what you would
say to the patient about her risk based on this test result? (select one)
 I am very concerned that this variant is the cause of the sudden death in your family
and your fainting episodes.
 At this point, we just don’t have enough information on this variant to determine if it
causing your symptoms and your family history, but I think it probably is.
 At this point, we don’t have enough information on this variant to determine for
certain if the gene change is causing your family history of sudden death and your
symptoms.
 Most VUS results end up being found to be normal variation that is not associated
with disease risk, but we just don’t have enough information to determine if this
variant is or is not responsible for your family and personal history.
 Other (please specify):
15. How likely is it that you would provide the following information to this patient after learning
the patient’s test result?
Not at
all likely
(1)

Somewhat
likely (2)

Moderately
likely (3)

What it
would mean
if the VUS is
later
reclassified
as
pathogenic
What it
would mean
if the VUS is
later
reclassified
as benign
Risk of
sudden
death (in
case the
VUS is later
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Very likely
(4)

Extremely
likely (5)

I don’t
know

classified as
pathogenic)
Risks of
undergoing
treatments
(in case the
VUS is later
classified as
benign)
Risks of
various
treatment
options for
ARVC
Penetrance
associated
with the
PKP2 gene
Allele
frequency of
the variant
Whether the
variant has
been found
in patients
with
symptoms
Information
on how the
gene change
may or may
not impact
the protein (if
available)
Whether the
change
occurred in a
site that is
highly
conserved
across
species
General
written
information
about VUS
results
General
written

41

information
about ARVC
Other
(please
specify):
16. How confident would you be in providing your input about medical evaluation and
management recommendations for this patient if you were asked to?
Not part of my clinical Not at all
Somewhat Moderately
Very
Extremely
role
confident
confident
confident
confident confident

17. Regardless of who makes the medical management decisions, how likely is it in your
clinic that a patient with this history from the scenario would be given the following
medical evaluation and management recommendations or options?
Not at
all likely
(1)

Somewhat
likely (2)

Moderately
likely (3)

Beta blockers
Implantable
cardioverterdefibrillator (ICD)
Cardiac catheter
ablation
Pacemaker
Evaluation by
Holter monitor
Cardiac MRI
Exercise stress test
Yearly ECGs
Yearly
echocardiograms
Yearly follow up
with a cardiologist
Clinical genetic
testing for family
members
Research genetic
testing for family
members
Cardiac evaluation
of other at-risk
family members
Limiting exercise
Dietary or weight
management
recommendations
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Very
Extremely
likely (4) likely (5)

I don’t
know

No medical
management
changes
Yearly follow up
with genetics to
determine if the
variant has been
reclassified
Other (please
specify):
18. How likely is it that you would use any of the following strategies with a patient like this
who has a VUS result?
Not at all
likely (1)

Somewhat
likely (2)

Check for patient
understanding
Identify sources of
uncertainty
Discuss how the VUS
may not help in
making treatment
decisions
Discuss the
uncertainty about the
most appropriate
medical management
Discuss the
uncertainty that can
come from variability
in the severity of
inherited cardiac
conditions
Discuss the
uncertainty about how
well medical
management will work
to prevent symptoms
(for example fainting
or sudden death)
Explore patient
concerns
Help patients create a
plan for dealing with
the uncertainty
Help patients identify
ways they can feel
more in control of
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Moderately
likely (3)

Very likely
(4)

Extremely
likely (5)

their life despite the
uncertainty
Referral for additional
longer term
counseling (social
worker/psychologist)
Other (please
specify):
19. How likely is it that you would encourage the patient to share the following information
with her family?
Not at all
likely (1)

Somewhat
likely (2)

Possibility of
having ARVC
based on family
history
Her own genetic
test report
Risk of sudden
death (in case the
VUS is later
classified as
pathogenic)
Risks of
undergoing
treatments (in case
the VUS is later
classified as
benign)
Inheritance pattern
of ARVC
Possible
symptoms of
AVRC
Penetrance
associated with the
PKP2 gene
Recommendation
that certain family
members consider
genetic counseling
Recommendation
for clinical genetic
testing of other
family members to
see who else has
the variant
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Moderately
likely (3)

Very likely
(4)

Extremely
likely (5)

Recommendation
of cardiac
evaluation for at
risk family
members
Other (please
specify):
20. Would the medical management recommendations and the information the patient is
encouraged to share with her family change if the variant appeared like it could be
pathogenic based on additional information you gathered or additional information
provided by the lab?
No
I don’t know
Yes, please explain:

Please use this space to describe how recommendations or information the patient is
encouraged to share with family might change ___________
21. Would the medical management recommendations and the information the patient is
encouraged to share with her family would change if the variant appeared like it may be
benign based on additional information you gathered or additional information provided
by the lab?
No
I don’t know
Yes, please explain:
Information Sources and Preference
22. Please indicate how often do think you would use the following resources when/if you
have a patient with a VUS result in an inherited arrhythmia or inherited cardiomyopathy
gene.
Never

Rarely

Supplemental information
included with test results from
the laboratory
Contact laboratory about variant
classification program
Contact researcher working in
this area of genetics
Search the scientific literature
for publications
Search variant databases
Discuss with colleague
Other (please specify):
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Sometimes

Often

Always

I
don’t
know

23. What would you find helpful in a variant database? (select all that apply)
Allele frequency
Computer modeling prediction of functional effect on protein
References to scientific publications
Results of segregation studies
Location of the variant (whether the variant is at a conserved region of the gene)
Type of mutation (missense, nonsense, frameshift)
Whether or not the variant was reported before
Whether the variant has been found in patients with symptoms (including the list of
symptoms)
Other (please specify):
24. How likely is it that you would use the following communication methods to help your
patient share information of results (pathogenic, likely pathogenic, VUS, likely benign,
benign) with their families?
Not at all
likely (1)

Somewhat
likely (2)

Moderately
likely (3)

Identifying
individuals
with whom
they may
want to
share the
information
Providing a
patient letter
to share with
family
members
Role playing
with patient
about how to
share
information
with family
members
Motivational
interviewing
Identifying
barriers to
sharing
information
and possible
ways to
overcome
them
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Very
likely (4)

Extremely
likely (5)

I don’t
know

Addressing
guilt/anxiety
about the
test result
Offer your
contact
information
to share with
family
members
Offer group
genetic
counseling
for the family
Other
(please
specify):

25. What additional information would you like to have available on Inherited Arrhythmia or
inherited cardiomyopathy VUS results to help you or your patients?

26. If you have any additional comments you would like to share with our research team,
please feel free to share them here.
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